Editas Medicine Inc - Asset Resilience Ratio
Editas Medicine Inc (EDIT) has an Asset Resilience Ratio of 0.00% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2025)
This chart shows how Editas Medicine Inc's Asset Resilience Ratio has changed over time. Check EDIT strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Editas Medicine Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Editas Medicine Inc (EDIT) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Editas Medicine Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Editas Medicine Inc Industry Peers by Asset Resilience Ratio
Compare Editas Medicine Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Prostemics Co. Ltd
KQ:203690 |
Biotechnology | 0.31% |
|
ORUM
KQ:475830 |
Biotechnology | 82.74% |
|
TELIX Pharmaceuticals Ltd
AU:TLX |
Biotechnology | 32.29% |
|
TG Therapeutics Inc
NASDAQ:TGTX |
Biotechnology | 4.72% |
|
Green Cross Holdings Preference Shares
KO:005257 |
Biotechnology | 0.50% |
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT |
Biotechnology | 33.70% |
|
NEWRON PHARMACEUT. EO-20
XETRA:NP5 |
Biotechnology | 41.67% |
|
Cybin Inc
NEO:CYBN |
Biotechnology | 0.21% |
Annual Asset Resilience Ratio for Editas Medicine Inc (2015–2025)
The table below shows the annual Asset Resilience Ratio data for Editas Medicine Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.00% | $0.00 | $186.53 Million | -- |
| 2024-12-31 | 40.51% | $138.37 Million | $341.59 Million | +0.55pp |
| 2023-12-31 | 39.96% | $199.46 Million | $499.15 Million | +0.54pp |
| 2022-12-31 | 39.42% | $202.75 Million | $514.32 Million | -4.32pp |
| 2021-12-31 | 43.74% | $296.33 Million | $677.48 Million | -2.09pp |
| 2020-12-31 | 45.83% | $262.43 Million | $572.60 Million | +2.80pp |
| 2019-12-31 | 43.03% | $218.96 Million | $508.88 Million | -12.68pp |
| 2018-12-31 | 55.71% | $234.18 Million | $420.39 Million | +6.81pp |
| 2017-12-31 | 48.90% | $182.51 Million | $373.26 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $229.18 Million | -- |
| 2015-12-31 | 0.21% | $320.00K | $149.36 Million | -- |
About Editas Medicine Inc
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The… Read more